Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00135772|
Recruitment Status : Completed
First Posted : August 26, 2005
Last Update Posted : January 12, 2017
|Condition or disease|
|Schizophrenia and Disorders With Psychotic Features Tobacco Use Disorder|
Schizophrenic individuals have higher urinary cotinine levels compared to non-schizophrenic individuals with a similar smoking history. This suggests that schizophrenic individuals may absorb higher doses of nicotine. The purpose of this study is to determine whether smokers with schizophrenia or schizoaffective disorder have higher serum nicotine and cotinine levels in comparison to smokers without schizophrenic-related disorders.
This observational, case-control study will enroll 150 participants, of which 100 will be smokers with schizophrenic-related disorders and 50 will be smokers without a mental illness. Upon completing baseline assessments, participants will smoke a single cigarette. Approximately two minutes following, 3 to 4 ounces of blood will be analyzed for nicotine and cotinine levels. An expired carbon monoxide reading will also be measured. This measurement correlates with the amount of smoke inhalation. Individual participant studies will be completed in 1 to 2 hour-long sessions.
|Study Type :||Observational|
|Enrollment :||100 participants|
|Official Title:||Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder|
|Study Start Date :||October 2003|
|Actual Primary Completion Date :||July 2004|
|Actual Study Completion Date :||July 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00135772
|United States, New Jersey|
|UMDNJ - Robert Wood Johnson Medical School|
|Piscataway, New Jersey, United States, 08854|
|Principal Investigator:||Jill M. Williams, M.D.||Rutgers, The State University of New Jersey|